1.66
-0.14 (-7.78%)
| Penutupan Terdahulu | 1.80 |
| Buka | 1.80 |
| Jumlah Dagangan | 139,458 |
| Purata Dagangan (3B) | 465,861 |
| Modal Pasaran | 1,670,906,112 |
| Harga / Buku (P/B) | 91.32 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Mar 2025 - 25 Mar 2025 |
| EPS Cair (TTM) | -0.540 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.45% |
| Nisbah Semasa (MRQ) | 17.08 |
| Aliran Tunai Operasi (OCF TTM) | -127.56 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -88.41 M |
| Pulangan Atas Aset (ROA TTM) | -20.37% |
| Pulangan Atas Ekuiti (ROE TTM) | -31.34% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | ProKidney Corp. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -1.63 |
|
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 27.44% |
| % Dimiliki oleh Institusi | 43.37% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Suvretta Capital Management, Llc | 30 Sep 2024 | 12,341,266 |
| Bleichroeder Lp | 30 Sep 2024 | 1,845,000 |
| Brown University | 30 Sep 2024 | 1,000,000 |
| Bank Of New York Mellon Corp | 30 Sep 2024 | 190,495 |
| Amundi | 30 Sep 2024 | 155,953 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |